Bilbo Patrick 4

4 · Organogenesis Holdings Inc. · Filed Feb 20, 2026

AI-generated summary of this filing

Updated Feb 20, 2026

Organogenesis (ORGO) COO Bilbo Patrick Receives Equity Awards

What Happened

Bilbo Patrick, Chief Operating Officer of Organogenesis Holdings, received multiple equity awards on Feb 18, 2026 and had shares withheld to cover tax withholding. Specifically, he was granted 210,937 restricted stock units (RSUs) (acquired, $0.00 per share), issued 48,612 shares upon settlement of a 2025 performance award (acquired, $0.00), and received a derivative award for 120,267 shares (acquired, $0.00). To cover tax liabilities, 16,212 shares were surrendered/withheld at $3.84 per share for a total of $62,254 (reported as a disposition for tax withholding).
These were awards (not open-market purchases or option exercises that generated cash proceeds). The RSUs and the derivative award have multi-year vesting/exercise schedules (see Key Details).

Key Details

Transaction date: Feb 18, 2026; Form 4 filed Feb 20, 2026 (filing appears timely).
Grants/issuances: 210,937 RSUs (F1), 48,612 shares from performance award settlement (F2), 120,267 derivative award (F3); all reported at $0.00 per share as awards.
Tax withholding: 16,212 shares disposed at $3.84 to cover taxes, totaling $62,254 (coded F = payment of exercise price or tax liability).
Shares owned after transaction: Not specified in the provided filing details.
Notable footnotes:
- F1: RSUs — each unit converts to one share upon vesting; RSUs vest in equal annual installments over four years beginning Feb 15, 2026.
- F2: 48,612 shares issued on vesting/settlement of a 2025 performance share award tied to performance milestones.
- F3: Derivative award (option-like) becomes exercisable in equal annual installments over four years beginning Feb 15, 2026.
No 10b5-1 plan or late filing indication was provided in the excerpt.

Context

The grants are routine equity compensation for executives and are not open-market purchases (which are sometimes viewed as stronger bullish signals). The 16,212-share disposal is a tax-withholding event, common when RSUs or performance shares vest and shares are withheld to satisfy tax obligations. The derivative award is subject to future vesting/exercise schedules and does not represent immediately tradable shares unless/until vested and exercised.

Form 4

Period: 2026-02-18

Chief Operating Officer

Transactions

Award
Class A Common Stock
[F1]
2026-02-18+210,937→ 1,095,585 total
Award
Class A Common Stock
[F2]
2026-02-18+48,612→ 1,144,197 total
Tax Payment
Class A Common Stock
2026-02-18$3.84/sh−16,212$62,254→ 1,127,985 total
Award
Stock Option (Right to Buy)
[F3]
2026-02-18+120,267→ 120,267 total
Exercise: $3.84Exp: 2036-02-18→ Class A Common Stock (120,267 underlying)

Footnotes (3)

[F1]Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026.
[F2]Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones.
[F3]The option becomes exercisable in equal annual installments over four years beginning February 15, 2026.

Signature

/s/ William R. Kolb, Attorney-in-Fact|2026-02-20

1 file